These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373 [TBL] [Abstract][Full Text] [Related]
8. [Lenvatinib in radioiodine refractory thyroid carcinomas]. de la Fouchardiere C Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859 [TBL] [Abstract][Full Text] [Related]
12. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Dadu R; Cabanillas ME Minerva Endocrinol; 2012 Dec; 37(4):335-56. PubMed ID: 23235190 [TBL] [Abstract][Full Text] [Related]
13. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer. Herranz UA Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):47-53. PubMed ID: 36202606 [TBL] [Abstract][Full Text] [Related]
14. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer. Hegazi M; Azadi A; Jain D; Redman R; Perez CA Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849 [TBL] [Abstract][Full Text] [Related]
16. Lenvatinib: Role in thyroid cancer and other solid tumors. Cabanillas ME; Habra MA Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514 [TBL] [Abstract][Full Text] [Related]
17. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. Wang E; Karedan T; Perez CA Anticancer Drugs; 2015 Aug; 26(7):689-97. PubMed ID: 25974026 [TBL] [Abstract][Full Text] [Related]
18. Update on thyroid cancer treatment. Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931 [TBL] [Abstract][Full Text] [Related]